While food shortage and malnutrition have been a common scenario throughout human history, the worldwide public health crisis caused by the epidemic of obesity is relatively recent.
Gaithersburg, Maryland-based Altimmune announced that the U.S. Food and Drug Administration cleared a Phase II clinical trial for the biopharmaceutical company’s investigational obesity-treating drug pemvidutide.
A study on weight loss suggests that, apart from body mass index (BMI), the likelihood that a person will fail or succeed at shedding the pounds is linked to the genetic makeup of one’s gut microbiome.
The pandemic is pushing more people to seek treatment for obesity, Novo Nordisk’s top boss said on Aug. 5, referring to strong sales of the newly launched drug Wegovy, which helped the drugmaker raise its earnings forecast for full-year 2021.
Novo Nordisk is positioning the company’s type 2 diabetes treatment Ozempic (semaglutide) as an anti-obesity treatment, as data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 analog significantly reduced weight in patients over the course of 68 weeks.
The U.S. Food and Drug Administration called for Eisai to pull the company’s Belviq and Belviq XR for weight loss from the market after clinical trials demonstrated an increased incidence of cancer in users.
A landmark French trial will seek to settle one of the country’s biggest pharmaceutical scandals, probing whether the company behind a weight-loss drug believed to have triggered killer side effects covered up the risks.
Tampa FL, June 10, 2015: Marketdata Enterprises, Inc., a leading independent market research publisher of “off-the-shelf” studies about service industries since 1979, has examined the diet market for 26 years, […]
